WO2013058632A3 - 폴리트리카스트럼 알피넘 유래 신규 화합물 오하이오넨신 f를 함유하는 동맥경화증 예방 또는 치료용 조성물 - Google Patents

폴리트리카스트럼 알피넘 유래 신규 화합물 오하이오넨신 f를 함유하는 동맥경화증 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2013058632A3
WO2013058632A3 PCT/KR2012/008686 KR2012008686W WO2013058632A3 WO 2013058632 A3 WO2013058632 A3 WO 2013058632A3 KR 2012008686 W KR2012008686 W KR 2012008686W WO 2013058632 A3 WO2013058632 A3 WO 2013058632A3
Authority
WO
WIPO (PCT)
Prior art keywords
polytrichastrum
alpinum
preventing
composition containing
ohioensins
Prior art date
Application number
PCT/KR2012/008686
Other languages
English (en)
French (fr)
Other versions
WO2013058632A2 (ko
Inventor
임정한
김일찬
김덕규
한세종
이형석
오현철
표석능
Original Assignee
한국해양연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국해양연구원 filed Critical 한국해양연구원
Priority to CN201280056382.9A priority Critical patent/CN104066429A/zh
Publication of WO2013058632A2 publication Critical patent/WO2013058632A2/ko
Publication of WO2013058632A3 publication Critical patent/WO2013058632A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 폴리트리카스트럼 알피넘 추출물을 함유하는 동맥경화증 예방 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 남극 이끼류인 폴리트리카스트럼 알피넘으로부터 분리된 벤조나프토크산테논계 화합물 오하이오넨신 F를 유효성분으로 함유하는 동맥경화증 예방 또는 치료용 약학 조성물에 관한 것이다. 본 발명에 따른 폴리트리카스트럼 알피넘(Polytrichastrum alpinum) 추출물 유래 벤조나프토크산테논계 화합물 오하이오넨신 F가 함유된 조성물은 TNF-α에 의해 유도되는 세포부착분자의 발현을 억제시킴으로써, 동맥경화증 치료 및 예방에 유용하게 사용할 수 있다.
PCT/KR2012/008686 2011-10-20 2012-10-22 폴리트리카스트럼 알피넘 유래 신규 화합물 오하이오넨신 f를 함유하는 동맥경화증 예방 또는 치료용 조성물 WO2013058632A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280056382.9A CN104066429A (zh) 2011-10-20 2012-10-22 含有源自拟金发藓的新化合物北美金发藓素f的用于预防或治疗动脉硬化症的组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0107526 2011-10-20
KR1020110107526A KR101354167B1 (ko) 2011-10-20 2011-10-20 폴리트리카스트럼 알피넘 유래 신규 화합물 오하이오넨신 ｆ를 함유하는 동맥경화증 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2013058632A2 WO2013058632A2 (ko) 2013-04-25
WO2013058632A3 true WO2013058632A3 (ko) 2013-06-20

Family

ID=48141572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/008686 WO2013058632A2 (ko) 2011-10-20 2012-10-22 폴리트리카스트럼 알피넘 유래 신규 화합물 오하이오넨신 f를 함유하는 동맥경화증 예방 또는 치료용 조성물

Country Status (3)

Country Link
KR (1) KR101354167B1 (ko)
CN (1) CN104066429A (ko)
WO (1) WO2013058632A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101938055B1 (ko) 2017-04-05 2019-01-14 성균관대학교산학협력단 개꼬시래기 추출물 또는 분획물을 유효성분으로 함유하는 동맥경화증의 예방 및 치료용 약학 조성물
KR101938056B1 (ko) 2017-04-05 2019-01-14 성균관대학교산학협력단 개꼬시래기 추출물 또는 분획물을 유효성분으로 함유하는 당뇨병의 예방 및 치료용 약학 조성물
CN115894284B (zh) * 2022-11-22 2023-05-30 河北中医学院 一种从台湾拟金发藓中分离的新化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050054266A (ko) * 2003-12-04 2005-06-10 한국생명공학연구원 실리마린을 함유하는 동맥경화의 치료 및 예방용 조성물
KR100957205B1 (ko) * 2007-11-14 2010-05-11 한국해양연구원 단백질 타이로신 탈인산화 효소 1ｂ를 저해하는벤조나프토크산테논계 화합물 및 그 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050054266A (ko) * 2003-12-04 2005-06-10 한국생명공학연구원 실리마린을 함유하는 동맥경화의 치료 및 예방용 조성물
KR100957205B1 (ko) * 2007-11-14 2010-05-11 한국해양연구원 단백질 타이로신 탈인산화 효소 1ｂ를 저해하는벤조나프토크산테논계 화합물 및 그 용도

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BHATTARAI, HD ET AL.: "In vitro antioxidant capacities of two benzonaphthoxanthenones: ohioensins F and G, isolated from the Antarctic moss Polytrichastrum alpinum", Z NATURFORSCH C., vol. 64, no. 3-4, March 2009 (2009-03-01) *
FRUEBIS, J ET AL.: "Inhibition ofVCAM-l expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits", JOURNAL OF LIPID RESEARCH, vol. 40, November 1999 (1999-11-01), pages 1958 - 1966 *
SEO CHANGON ET AL.: "Ohioensins F and G: Protein tyrosine phosphatase 1B inhibitory benzonaphthoxanthenones from the Antarctic moss Polytrichastrum alpinum", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 18, 17 November 2007 (2007-11-17), pages 272 - 775 *
ZHANG, F ET AL.: "Inhibition ofTNF-a induced ICAM-1, VCAM-1 and E-selectin expression by selenium", ATHEROSCLEROSIS, vol. 161, no. 2, April 2002 (2002-04-01), pages 381 - 386 *

Also Published As

Publication number Publication date
KR20130043415A (ko) 2013-04-30
CN104066429A (zh) 2014-09-24
WO2013058632A2 (ko) 2013-04-25
KR101354167B1 (ko) 2014-01-27

Similar Documents

Publication Publication Date Title
WO2014014835A8 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
WO2013066835A3 (en) Compounds and methods
WO2013066839A3 (en) Compounds and methods
EA201390198A1 (ru) Гетероциклическое соединение
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
WO2012157978A3 (ko) 팥꽃나무 추출물, 이의 분획물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 아토피 예방 또는 치료용 약학적 조성물
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
WO2011159137A3 (ko) 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
EP3207928A4 (en) Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
WO2012104240A3 (de) Kosmetische verwendung
WO2011159129A3 (ko) 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
WO2013169631A3 (en) Wnt protein signalling inhibitors
WO2014186450A3 (en) Highly potent inhibitors of porcupine
WO2012074249A3 (ko) 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Ｒａｆ키나제의 저해활성을 가지는 약학적 조성물
PH12016502544A1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
WO2013058632A3 (ko) 폴리트리카스트럼 알피넘 유래 신규 화합물 오하이오넨신 f를 함유하는 동맥경화증 예방 또는 치료용 조성물
EP3006434A4 (en) Novel compound derived from plant of genus quamoclit and composition containing same as active ingredient for preventing or treating diabetes
WO2012173382A3 (ko) 탄시논ⅱａ를 유효성분으로 함유하는 피부 외용제 조성물
WO2012154879A3 (en) Autophagy inhibitors
MX2013004878A (es) N-hetarilmetil pirazolilcarboxamidas.
EA201591180A1 (ru) Составы ингибитора lfa-1
WO2014047519A3 (en) Inhibitors of beta-hydrolase for treatment of cancer
WO2013006526A3 (en) Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
WO2010075086A3 (en) Pyrrolidinone inhibitors of pde-4
WO2014065640A3 (ko) 외톨개모자반 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환 치료 또는 예방용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12841746

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12841746

Country of ref document: EP

Kind code of ref document: A2